On June 10, 2025 Foresight Diagnostics, a leading developer of ultra-sensitive minimal residual disease (MRD) detection technologies, reported that validation data demonstrating the prognostic performance of its CLARITY MRD assay in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) will be featured as encore oral presentations at two upcoming international conferences: the 2025 European Hematology Association (EHA) (Free EHA Whitepaper) Congress (June 12–15, in Milan, Italy) and the 18th International Conference on Malignant Lymphoma (ICML) (June 17–21, in Lugano, Switzerland) (Press release, Foresight Diagnostics, JUN 10, 2025, View Source [SID1234653798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This multi-center study, conducted in collaboration with Amsterdam University Medical Centers, the Hemato-Oncology Foundation for Adults in the Netherlands (HOVON), and the Netherlands Comprehensive Cancer Organization (IKNL), highlights real-world results using Foresight CLARITY MRD on patients who were treated with frontline chemotherapy across over 50 centers in the Netherlands and Belgium.

"We’re grateful to present our data at major medical meetings this spring, validating our science and the real-world utility of ultra-sensitive ctDNA-MRD technology," said David Kurtz, M.D., Ph.D., Chief Medical Officer of Foresight Diagnostics. "These presentations and the recent incorporation of ctDNA-MRD testing in B-cell lymphoma clinical guidelines give us confidence as we prepare to launch in the clinical market in 2026 and integrate Foresight CLARITY into routine clinical practice."

Lead study authors Steven Wang, M.D., and Martine Chamuleau, M.D., Ph.D., Amsterdam UMC, added: "Our findings confirm that ultra-sensitive ctDNA-MRD detection provides meaningful prognostic information beyond standard imaging and clinical factors. We believe this assay can support better risk stratification than imaging alone and inform post-treatment management decisions in DLBCL."

Oral presentation details for EHA (Free EHA Whitepaper):

Title: Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial
Presenter: Martine Chamuleau, MD, PhD (Amsterdam UMC)
Session: Aggressive Non-Hodgkin lymphoma – Clinical (Observational)
Time: Thursday, June 12 | 5:00 p.m. – 5:15 p.m. CEST / 11:00 a.m. – 11:15 a.m. ET
Room: Brown Hall 3
Abstract number: S240
Oral presentation details for ICML:

Title: Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national HOVON trial
Presenter: Martine Chamuleau, MD, PhD (Amsterdam UMC)
Session: Session 6: Liquid biopsy for response assessment
Time: Thursday, June 19 | 2:15 p.m. – 2:30 p.m. CEST / 8:15 a.m. – 8:30 a.m. ET
Room: Polivalente room, East Campus USI
Article number: 041
In addition to the oral presentation, Foresight’s technology will be highlighted in other presentations, including:

Title: Prognostic Value of Circulating Tumor DNA (ctDNA) Detection by PhasED-Seq After Axicabtagene ciloleucel (Axi-cel) Therapy in Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Meeting: EHA (Free EHA Whitepaper) 2025
Sponsor: Kite Pharma
Presenter: Jeffrey Gregg, MD (Foresight Diagnostics)
Session: Poster Session I | Poster Hall
Date/Time: Friday, June 13 | 6:30 p.m. – 7:30 p.m. CEST / 12:30 p.m. – 1:30 p.m. ET
Abstract: #PF1002

Title: The Correlation of Mutational Profiles and Valemetostat Efficacy in Patients With R/R PTCL in the Phase 2 VALENTINE-PTCL01 Trial
Meeting: ICML 2025
Sponsor: Daiichi Sankyo
Presenter: Pier Luigi Zinzani, MD, PhD (University of Bologna)
Session: "Focus On" Session Biology and Therapy of T-cell Lymphomas | Room B
Date/Time: Saturday, June 14 | 10:05 a.m. – 10:15 a.m. CEST / 4:05 a.m. – 4:15 a.m. ET
Article Number: 164